BIOFILCHEM vs JAGSNPHARM: Stock Comparison
JAGSONPAL PHARMACEUTICALS is the larger company by market capitalisation. JAGSONPAL PHARMACEUTICALS shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BIOFILCHEM leads 0; JAGSNPHARM leads 9 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BIOFILCHEM | JAGSNPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BIOFILCHEM | JAGSNPHARM |
|---|---|---|
| Live Price | ₹29.48 | ₹215.1 |
| Day Change | 0.24% | -3.08% |
| Volume | 1,662 | 34,195 |
| 52-Week High | ₹46.34 | ₹264.5 |
| 52-Week Low | ₹25.6 | ₹155 |
| Distance from 52W High | -36.38% | -18.68% |
Valuation
| Metric | BIOFILCHEM | JAGSNPHARM |
|---|---|---|
| Market Cap | ₹46 Cr | ₹1,428 Cr |
| P/E Ratio | — | 32.35x |
| P/B Ratio | — | 6.09x |
| EPS | ₹0.17 | ₹2 |
| Book Value | ₹13.21 | ₹41.95 |
| Dividend Yield | 0% | 1.8% |
Growth
| Metric | BIOFILCHEM | JAGSNPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | -9.3% | 9.6% |
| EPS Growth (TTM YoY) | 10.8% | 23.8% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | BIOFILCHEM | JAGSNPHARM |
|---|---|---|
| ROE | 12.92% | 15.6% |
| ROCE | 11.39% | 16.48% |
| Net Margin | 9.81% | 15% |
| Operating Margin | 12.18% | 20.38% |
| Debt to Equity | 0.14x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BIOFILCHEM | JAGSNPHARM |
|---|---|---|
| Promoter Holding | 46.79% | 25.46%▼ 0.09 pp |
| FII Holding | 0% | 2.14%▼ 0.16 pp |
| DII Holding | 0.08% | 1.65%▲ 1.03 pp |
| Public Holding | 53.13% | 27.4%▼ 0.63 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BIOFIL CHEM & PHARMA and JAGSONPAL PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.